Adaptive Biotechnologies (ADPT) Profit After Tax (2018 - 2026)

Adaptive Biotechnologies has reported Profit After Tax for 9 years, with the latest figure at -$20.0 million in Q1 2026.

• Quarterly Profit After Tax rose 32.9% year-over-year to -$20.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$49.7 million (up 64.96% YoY) and the FY2025 annual result came in at -$59.5 million, up 62.72% from the prior year.
• Profit After Tax fell to -$20.0 million in Q1 2026 per ADPT's latest filing, from -$13.6 million in the prior quarter.
• Over five years, Profit After Tax peaked at $9.5 million in Q3 2025 and troughed at -$69.4 million in Q4 2023.
• A 5-year average of -$39.1 million and a median of -$45.3 million in 2022 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2023 and 2025: Profit After Tax plunged 72.87% in 2023, then surged 129.76% in 2025.
• Over 5 years, Profit After Tax stood at -$40.2 million in 2022, then slumped by 72.87% to -$69.4 million in 2023, then jumped by 51.45% to -$33.7 million in 2024, then soared by 59.6% to -$13.6 million in 2025, then tumbled by 46.94% to -$20.0 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$20.0 million, -$13.6 million, and $9.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.